<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650662</url>
  </required_header>
  <id_info>
    <org_study_id>CYCLE (IRFMN_5635)</org_study_id>
    <secondary_id>2011-002876-18</secondary_id>
    <nct_id>NCT01650662</nct_id>
  </id_info>
  <brief_title>CYCLosporinE A in Reperfused Acute Myocardial Infarction</brief_title>
  <acronym>CYCLE</acronym>
  <official_title>CYCLosporinE A in Reperfused Acute Myocardial Infarction Prospective, Controlled, Randomized, Multicentre Trial to Examine Whether a Single i.v. Bolus of Cyclosporine A Before PCI Can Reduce Myocardial Reperfusion Injury in Patients With STEMI.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart Care Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infarct size is a major determinant of prognosis after myocardial infarction (MI). It has&#xD;
      been reported that Cyclosporine A (CsA) administered immediately prior to percutaneous&#xD;
      coronary intervention (PCI) significantly could reduce reperfusion injury and consequently&#xD;
      infarct size in ST elevation MI (STEMI) patients.&#xD;
&#xD;
      CYCLE trial is a multicenter, controlled, randomized open label study, with blind assessment&#xD;
      of endpoint measures. The objective is to determine whether a single i.v. dose of CsA within&#xD;
      6 hour onset of symptoms of STEMI in 444 patients, improves outcomes after successful primary&#xD;
      PCI, by reducing myocardial injury associated to reperfusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The possibility of optimizing the results of an early and effective reopening of the occluded&#xD;
      artery by reducing/avoiding the impact of the so-called reperfusion injury has been for many&#xD;
      years one of the most elusive objectives of pharmacological research, with evolving&#xD;
      hypothesis and targets.&#xD;
&#xD;
      A recently published trial has provided support to a line of investigation focused on the&#xD;
      role of mitochondrial dysfunction, the so-called permeability transition, as cause of&#xD;
      irreversible myocardial injury associated to reperfusion. In fact, a single dose of the&#xD;
      widely used immunosuppressant agent, CsA, a potent inhibitor of mitochondrial permeability&#xD;
      transition pore opening, was reported to limit ischemia-reperfusion injury in 50 patients&#xD;
      with anterior MI who underwent primary PCI.&#xD;
&#xD;
      Since infarct size and left ventricular function are the main determinants of long-term&#xD;
      morbidity and mortality, a single measure to limit infarct size is of potential clinical&#xD;
      benefit. Therefore the results of the previously mentioned trial should be replicated in a&#xD;
      larger sample size, before going on to a trial with clinical endpoints.&#xD;
&#xD;
      - Sample size&#xD;
&#xD;
      Assuming an incidence of the primary endpoint of 55% in the control group, we calculated that&#xD;
      444 patients (222 patients per group) will be required for the study to have 80% power to&#xD;
      detect a 25% relative improvement (resulting in an endpoint frequency of 68.7% in the CsA&#xD;
      group) with a 5% drop-out rate and a two-sided alpha level of 5%. The size of the trial will&#xD;
      allow to investigate treatment benefit for the secondary endpoint hsTnT: assuming a&#xD;
      concentration of 2.7 ng/mL on day 4 (common SD=2.1) in the control group, the study will have&#xD;
      a 90% power to show a 25% reduction with CsA at a two-sided alpha level of 5%.&#xD;
&#xD;
      - Safety&#xD;
&#xD;
      Adverse events with intravenous CsA (i.e. anaphylactoid reactions/anaphylactic shock, acute&#xD;
      renal failure, or hypertensive crisis) are reported to be very rare. In this trial, patients&#xD;
      will receive only one iv dose of CsA, therefore we expect a low probability of adverse&#xD;
      effects related to repeated administrations, i.e. acute renal failure or hypertensive crisis.&#xD;
      Nonetheless a close monitoring of the safety of the single dose of CsA is foreseen with&#xD;
      monthly examination of data of safety by the Steering Committee.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of myocardial reperfusion, measured with ST-segment resolution &gt;=70%</measure>
    <time_frame>1 hour after percutaneous coronary intervention (PCI)</time_frame>
    <description>Improvement of myocardial reperfusion, measured with ST-segment resolution &gt;=70% 1 hour after PCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High sensitive cardiac troponin T (hs-cTnt).</measure>
    <time_frame>at day 4 after percutaneous coronary intervention (PCI)</time_frame>
    <description>High sensitive cardiac troponin T (hs-cTnt) at day 4 after PCI; ; this will be the most relevant among secondary endpoints given its value as readout of cardiac protection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical events: all-cause mortality, HF or shock; rehospitalization for CV reasons</measure>
    <time_frame>within 6 months of randomization</time_frame>
    <description>Clinical events within 6 months of randomization: all-cause mortality, HF or shock; rehospitalization for CV reasons.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct size: Troponin curve (T or I, assayed locally)</measure>
    <time_frame>Time course of troponin release during the first 72 hours after the visualization of the antegrade flow.</time_frame>
    <description>Infarct size: Troponin curve (T or I, assayed locally); The time course of troponin release during the first 72 hours after the visualization of the antegrade flow, will be studied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV remodeling and function as assessed by echocardiography;</measure>
    <time_frame>at 6 months after randomization</time_frame>
    <description>LV remodeling and function at 6 months, as assessed by echocardiography;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No reflow, as assessed by myocardial blush</measure>
    <time_frame>1 day (after the visualization of the antegrade flow)</time_frame>
    <description>No reflow, as assessed by myocardial blush after the visualization of the antegrade flow</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">410</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Cyclosporine A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigational active treatment is CsA, an immunosuppressant indicated for the prevention of acute rejection after organ transplant, including cardiac transplantation.&#xD;
The preparation used in the trial will be Sandimmun IV, containing CsA 50 mg/ml, CremophorÂ® EL and 94% ethyl alcohol in a 5 ml vial.&#xD;
Patients will received Cyclosporine A on the top of recommended standard care for acute myocardial infarction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The control group received on the top of recommended standard care for acute myocardial infarction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine A</intervention_name>
    <description>In the CsA group, at least 5 min before balloon inflation and stenting, patients will receive an intravenous bolus injection of 2.5 mg/kg of CsA. In the control group, patients will receive only recommended treatments. CsA will be dissolved in normal NaCl 0.9% solution (final concentration 25 mg/ml) and injected slowly (over 20-30 seconds) via a catheter positioned in an antecubital vein at least 5 min before PCI, to allow for distribution of the drug.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Cyclosporine A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients with large STEMI not older than 6 hours, defined as&#xD;
&#xD;
          -  angina pectoris or equivalent symptoms of more than 20 minutes duration within last 6&#xD;
             hours, and&#xD;
&#xD;
          -  ST elevation in at least 3 leads in anterior MI and/or a deviation in at least 4 leads&#xD;
             in inferior MI,&#xD;
&#xD;
          -  TIMI flow 0 or 1 in identified culprit artery&#xD;
&#xD;
          -  Intended acute primary PCI&#xD;
&#xD;
          -  Age â¥ 18 years&#xD;
&#xD;
          -  Ability to understand the nature, scope, and possible consequences of the study&#xD;
             participation/legal capacity&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Left bundle branch block&#xD;
&#xD;
          -  TIMI flow &gt; 1 in the identified culprit artery&#xD;
&#xD;
          -  Treatment with CsA within last 10 days&#xD;
&#xD;
          -  Contraindication to CsA or history of allergic reaction to CsA&#xD;
&#xD;
          -  Coronary anatomy not suitable for PCI&#xD;
&#xD;
          -  Thrombolytic therapy within 24 h. before randomization&#xD;
&#xD;
          -  Previous MI&#xD;
&#xD;
          -  Previous CABG&#xD;
&#xD;
          -  Severe renal or hepatic insufficiency&#xD;
&#xD;
          -  Malignant tumor, not curatively treated&#xD;
&#xD;
          -  Women with childbearing potential, esp. pregnant or nursing women&#xD;
&#xD;
          -  Participation in another clinical or device trial within the previous 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Latini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mario Negri Institute, Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Filippo Ottani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale G.B. Morgagni, Pierantoni, ForlÃ¬, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Regionale Umberto Parini</name>
      <address>
        <city>Aosta</city>
        <state>AO</state>
        <zip>11100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Donato</name>
      <address>
        <city>Arezzo</city>
        <state>AR</state>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Paolo</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Seriate</name>
      <address>
        <city>Seriate</city>
        <state>BG</state>
        <zip>24068</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Treviglio</name>
      <address>
        <city>Treviglio</city>
        <state>BG</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S.Marco</name>
      <address>
        <city>Zingonia - Osio Sotto</city>
        <state>BG</state>
        <zip>24040</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Fondazione Poliambulanza</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera G.Brotzu</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <zip>09100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <state>CN</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale delle Misericordie</name>
      <address>
        <city>Grosseto</city>
        <state>GR</state>
        <zip>58100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Campo di Marte</name>
      <address>
        <city>Lucca</city>
        <state>LU</state>
        <zip>55100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Desio</name>
      <address>
        <city>Desio</city>
        <state>MB</state>
        <zip>20832</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Monza</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOR Villa Sofia - Cervello P.O.</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOR Villa Sofia - Cervello PO Villa Sofia</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile dello Spirito Santo</name>
      <address>
        <city>Pescara</city>
        <state>PE</state>
        <zip>65100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <state>RA</state>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Camillo</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Infermi</name>
      <address>
        <city>Rimini</city>
        <state>RN</state>
        <zip>47921</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Corona</name>
      <address>
        <city>Pietra Ligure</city>
        <state>SV</state>
        <zip>17027</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Chiara</name>
      <address>
        <city>Trento</city>
        <state>TN</state>
        <zip>38100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi</name>
      <address>
        <city>Rivoli</city>
        <state>TO</state>
        <zip>10098</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maria Vittoria</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Ospedale Riuniti</name>
      <address>
        <city>Trieste</city>
        <state>TS</state>
        <zip>34121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giacomo</name>
      <address>
        <city>Castelfranco Veneto</city>
        <state>TV</state>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ca' Foncello</name>
      <address>
        <city>Treviso</city>
        <state>TV</state>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera -Univ. S. Maria delle Misericordie</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <zip>33200</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale dell'Angelo</name>
      <address>
        <city>Mestre</city>
        <state>VE</state>
        <zip>30100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale G.B. Morgani - L. Pierantoni</name>
      <address>
        <city>Forli</city>
        <zip>47100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.anmco.it</url>
    <description>The protocol presentation, can be found in the window of CYCLE Study.</description>
  </link>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <last_update_submitted>April 15, 2015</last_update_submitted>
  <last_update_submitted_qc>April 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>Cyclosporine A</keyword>
  <keyword>Reperfusion</keyword>
  <keyword>Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

